

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Bretisilocin
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : AbbVie Inc
Deal Size : $1,200.0 million
Deal Type : Acquisition
AbbVie to Acquire Gilgamesh Bretisilocin, a Novel, Investigational Therapy
Details : AbbVie will GM-2505 (bretisilocin) acquire Gilgamesh's lead investigational candidate, currently in development for the treatment of patients with moderate-to-severe major depressive disorder.
Product Name : GM-2505
Product Type : Miscellaneous
Upfront Cash : Undisclosed
August 25, 2025
Lead Product(s) : Bretisilocin
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : AbbVie Inc
Deal Size : $1,200.0 million
Deal Type : Acquisition
